Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(23):1684-1685; doi:10.1093/jnci/djj511
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tuma, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tuma, R. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

Testing Ways to Trigger Cell Death From the Outside

Rabiya S. Tuma

The first 10% of the full text of this article appears below.

Cells have two partially overlapping pathways that can induce programmed cell death. One of those branches is blocked by mutations in the p53 gene, which occur in more than half of tumors. So far scientists have been unable to find safe methods to activate the other branch.

That obstacle may be changing. Three drugs in early clinical trials are designed to activate "death receptors" on the cell's surface, the p53-independent pathway. The drugs—one small molecule and two monoclonal antibodies—appear relatively safe, and evidence from phase I and II trials suggests that the agents are active in a variety of tumor types.

"The proapoptotic death receptors represent a novel target for anticancer therapy," said Roy S. Herbst, M.D. Ph.D., chief of thoracic medical oncology at the University of Texas . . . [Full Text of this Article]

Small-Molecule Approach

Activating Antibodies

Hitch in the Plan?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?